As a medical oncologist who has practiced in three different countries, Dr. Maria Alice Franzoi is well acquainted with ...

We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Shares of Gilead Sciences Inc. GILD advanced 2.77% to $106.50 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.79% to 5,405.97 ...

Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. | Gilead Sciences’ sponsorship of a ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $120.00. The company’s shares closed yesterday at $111.89.

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top HIV drug maker Gilead Sciences last week. But, according to analysts at ...

In the latest trading session, Gilead Sciences (GILD) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day.

Gilead Sciences (NASDAQ:GILD) had reported double-digit growth in two areas of its commercial products portfolio when it released its Q4 and Full-year 2024 earnings back on February 11th of 2025.